论文部分内容阅读
目的:筛选都梁缓释贴剂的基质及透皮促渗剂。方法:采用L9(34)正交试验,运用药物溶出度仪和Franz扩散池,以贴剂中欧前胡素的体外释放度和经皮渗透量为评价指标,优选贴剂基质和透皮促渗剂。结果:都梁缓释贴剂基质和透皮促渗剂的最佳处方为:淀粉、羧甲基纤维素钠、甘油、氮酮、丙二醇和PEG400的质量百分含量分别为6%、2%、30%、1%、15%、2.5%,释药行为符合Higuchi方程,具有明显的缓释特征。结论:都梁缓释贴剂具有很好的体外缓释效果及体外透皮特性,贴剂稳定性较好,可进一步考察其体内释药行为。
OBJECTIVE: To screen the matrix and transdermal penetration enhancers of Duliang sustained-release patch. Methods: L9 (34) orthogonal test was used to evaluate the in vitro release and transdermal permeation of midopastin in patch preparation by using drug dissolution tester and Franz diffusion cell. Agent. Results: The best prescription of both Duliang sustained-release patch matrix and transdermal penetration enhancer was 6%, 2% and 5% respectively of starch, sodium carboxymethylcellulose, glycerol, azone, propylene glycol and PEG400, , 30%, 1%, 15% and 2.5%, respectively. The drug release behavior accorded with Higuchi equation and had obvious sustained release characteristics. Conclusion: Duliang sustained-release patch has a good in vitro sustained-release effect and in vitro transdermal properties, the stability of the patch is better, and its release behavior in vivo can be further investigated.